This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064203%3A_____%2F10%3A6069%21RIV11-MZ0-00064203/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064203%3A_____%2F10%3A6069%21RIV11-MZ0-00064203
rdf:type
skos:Concept n12:Vysledek
dcterms:description
We aimed at characterizing the pharmacokinetics for daunorubicin in infants with ALL and examined their relationship to age, body weight, and body surface area. No age-dependency in any of the BSA-normalized pharmacokinetic parameters was observed. Consequently, due to the empirical dose reduction in infants the overall exposure to daunorubicinol in infants was smaller than would be expected from older children. We observed no indication of an age-dependency in the pharmacokinetics of daunorubicin. We aimed at characterizing the pharmacokinetics for daunorubicin in infants with ALL and examined their relationship to age, body weight, and body surface area. No age-dependency in any of the BSA-normalized pharmacokinetic parameters was observed. Consequently, due to the empirical dose reduction in infants the overall exposure to daunorubicinol in infants was smaller than would be expected from older children. We observed no indication of an age-dependency in the pharmacokinetics of daunorubicin.
dcterms:title
Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol
skos:prefLabel
Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol
skos:notation
RIV/00064203:_____/10:6069!RIV11-MZ0-00064203
n3:aktivita
n8:I
n3:aktivity
I
n3:cisloPeriodika
3
n3:dodaniDat
n4:2011
n3:domaciTvurceVysledku
n13:4977939
n3:druhVysledku
n6:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
278711
n3:idVysledku
RIV/00064203:_____/10:6069
n3:jazykVysledku
n16:eng
n3:klicovaSlova
daunorubicin; infants; leukemia; pharmacokinetics; acute lymphoblastic-leukemia; risk-factors; model; therapy; cardiotoxicity; quantification; doxorubicin; ly335979
n3:klicoveSlovo
n5:risk-factors n5:acute%20lymphoblastic-leukemia n5:infants n5:model n5:ly335979 n5:therapy n5:doxorubicin n5:cardiotoxicity n5:leukemia n5:quantification n5:pharmacokinetics n5:daunorubicin
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[2CE408195166]
n3:nazevZdroje
Pediatric Blood & Cancer
n3:obor
n10:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
9
n3:rokUplatneniVysledku
n4:2010
n3:svazekPeriodika
54
n3:tvurceVysledku
Hempel, G. Relling, M. V. Pieters, R. Barisone, E. De Lorenzo, P. Valsecchi, MG de Rossi, G. Boos, J. Starý, Jan
n3:wos
000274421400006
s:issn
1545-5009
s:numberOfPages
6